



READDI

Rapidly Emerging Antiviral Drug
Development Initiative



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

Without bold action now, the next pandemic is inevitable

- Novel viruses are emerging more frequently
- Viruses can emerge from anywhere
- The costs are staggering
- Response to COVID-19 continues to reveal multiple system failures

**The world urgently needs
a better solution.**



The current system is not optimized for pandemics

- Pharma is reluctant to invest in products with no obvious market
- University research funding (e.g. NIH) is project-based aimed at point solutions
- Governments cycle between panic and neglect

To achieve pandemic preparedness, we must re-engineer antiviral therapeutic development and delivery.



BOLD. SCIENTIFIC. PROACTIVE.

The solution is READDI

READDI brings together the world's best scientific and business minds to proactively develop and deliver novel antiviral drugs BEFORE the next virus creates another global catastrophe.



READDI is a public-private partnership

CEPI

Vaccines

Coalition for Epidemic
Preparedness

CARB-X

Antibiotics

Combating Antibiotic-
Resistant Bacteria



READDI

Antivirals

Rapidly Emerging Antiviral
Drug Development Initiative



What will READDI do?

Accelerate new antiviral drug development

Target factors that viruses need to replicate

Fund and facilitate projects at all stages

Aggregate and advance existing assets

Identify promising antiviral compounds shelved by industry

Develop stalled antivirals from academic labs


Expedite treatment availability

Prepare Phase II & III trial design

Identify manufacturing partners in advance



The READDI approach



Preparation

- Fund cross-sector science teams
- Complete antiviral drug development through Phase I (unless existing market opportunity)
- Put promising new and existing compounds on the shelf

Streamlined Execution

- Licensing
- Clinical trial design completed
- Trial sites designated
- Private sector partners in place



We're already collaborating for success



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

Industry Partners



University Partners



Strategic Partners



Industry collaboration ramps up

- 20+ active projects with partners from around the world
- Focus on multiple viral families with high pandemic potential
- Projects with JNJ and Takeda
- Emerging Industry consortium, “The Intrepid Alliance”. Newly formed LLC with as many as 10 Pharma partners



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

Johnson & Johnson



ONE TIME STATE FUNDING REQUEST (\$50M)



Governor Roy Cooper  @NC_Governor · May 19

...

We know that to grow we must innovate. This budget looks to the future by including funding for health research within the UNC System. UNC Chapel Hill is a worldwide leader in developing antiviral drugs that fight against diseases like COVID-19.



Governor Roy Cooper  @NC_Governor · May 19

...

This proposal would take our university researchers to a new level by funding the Rapidly Emerging Antiviral Drug Development Initiative (READDI), which will attract more private and federal funding, create good-paying jobs and help discover lifesaving drugs.



**SUPPORTS BIPARTISAN FEDERAL APPROPRIATIONS
EFFORT LED BY SENATOR BURR & REP. PRICE**

What Does This Mean to NC?

Highly-visible, global start-up headquartered in RTP

- NC and UNC are recognized around the globe for excellence in pandemic preparedness

Stimulate start-up activity

- New drug development & therapeutic screening

Increase research activity in NC

- Clinical trial and research activity managed by NC-based CROs

Develop drug manufacturing capabilities

Creation of sustainable revenue streams to drive long term growth



When the next virus emerges

On Day 1 we will have:

- Effective antiviral therapies through Phase I
- Established manufacturing plan
- Phase II & III clinical trials designed
- Plans for global response and equitable distribution



Will you help us prepare for the next pandemic?

Nat Moorman
co-founder
nmoorman@med.unc.edu
919-962-4920

John Bamforth
Executive director
johnph@email.unc.edu
919-866-7878



READDI